Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status
Eric M. Parker(University of New Hampshire), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Margaret van Heek
Cited by 97
Related Papers
Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation
|Journal of Biological Chemistry|2004|716
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
|Journal of Pharmacology and Experimental Therapeutics|2015|336
Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells.
|Journal of Biological Chemistry|1991|283
Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists.
|Journal of Biological Chemistry|1990|230